The story of CD4+CD28- T cells revisited: Solved or still ongoing?

Journal of Immunology Research

Volumn 2015, Issue , 2015, Pages

  Maly, Kathrin ^a   Schirmer, Michael ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; CD137 ANTIGEN; CD28 ANTIGEN; CD47 ANTIGEN; CELL ADHESION MOLECULE; CHEMOKINE RECEPTOR; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LYMPHOCYTE ANTIBODY; NATURAL KILLER CELL RECEPTOR; OLIGOCLONAL BAND; OX40 LIGAND; TOLL LIKE RECEPTOR;

ANKYLOSING SPONDYLITIS; APOPTOSIS; ATHEROSCLEROTIC PLAQUE; BRONCHIOLITIS OBLITERANS; CD4 POSITIVE CD28 NEGATIVE T LYMPHOCYTE; CELL AGING; CELL FUNCTION; CELL INTERACTION; CYTOMEGALOVIRUS INFECTION; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DISEASE SEVERITY; EFFECTOR CELL; HEART INFARCTION; HUMAN; MEMORY CELL; PHENOTYPE; PRIMARY SCLEROSING CHOLANGITIS; PROTEIN INTERACTION; REVIEW; RHEUMATOID ARTHRITIS; SUDDEN CARDIAC DEATH; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; UNSTABLE ANGINA PECTORIS; CD4+ T LYMPHOCYTE; CLONAL EVOLUTION; DISEASE PREDISPOSITION; DRUG EFFECTS; IMMUNOLOGY; LYMPHOCYTE COUNT; METABOLISM; T LYMPHOCYTE SUBPOPULATION;

ANTIGENS, CD28; CD4-POSITIVE T-LYMPHOCYTES; CELL AGING; CLONAL EVOLUTION; DISEASE SUSCEPTIBILITY; HUMANS; LYMPHOCYTE COUNT; PHENOTYPE; T-LYMPHOCYTE SUBSETS;

EID: 84925337173     PISSN: 23148861     EISSN: 23147156     Source Type: Journal    
DOI: 10.1155/2015/348746     Document Type: Review

References (114)

1. D. Schmidt, J. J. Goronzy, and C. M. Weyand, "CD4+ CD7-CD28-T cells are expanded in rheumatoid arthritis and are characterized by autoreactivity," The Journal of Clinical Investigation, vol. 97, no. 9, pp. 2027-2037, 1996.
2. D. Schmidt, P. B. Martens, C. M. Weyand, and J. J. Goronzy, "The repertoire of CD4+ CD28-T cells in rheumatoid arthritis," Molecular Medicine, vol. 2, no. 5, pp. 608-618, 1996.
3. K. J. Warrington, A.N. Vallejo, C. M. Weyand, and J. J. Goronzy, "CD28 loss in senescentCD4+ T cells: reversal by interleukin-12 stimulation," Blood, vol. 101, no. 9, pp. 3543-3549, 2003.
4. A. N. Vallejo, J. C. Brandes, C. M. Weyand, and J. J. Goronzy, "Modulation of CD28 expression: distinct regulatory pathways during activation and replicative senescence," The Journal of Immunology, vol. 162, no. 11, pp. 6572-6579, 1999.
5. A. N. Vallejo, A. R. Nestel, M. Schirmer, C. M. Weyand, and J. J. Goronzy, "Aging-related deficiency of CD28 expression in CD4+ T cells is associated with the loss of gene-specific nuclear factor binding activity," The Journal of Biological Chemistry, vol. 273, no. 14, pp. 8119-8129, 1998.
6. A. N. Vallejo, E. Bryl, K. Klarskov, S. Naylor, C.M. Weyand, and J. J. Goronzy, "Molecular basis for the loss of CD28 expression in senescent T cells," The Journal of Biological Chemistry, vol. 277, no. 49, pp. 46940-46949, 2002.
7. R. Javahery, A. Khachi, K. Lo, B. Zenzie-Gregory, and S. T. Smale, "DNA sequence requirements for transcriptional initiator activity in mammalian cells," Molecular and Cellular Biology, vol. 14, no. 1, pp. 116-127, 1994.
8. +T cells-characterization of an effector memory T-cell population in patients with rheumatoid arthritis," Scandinavian Journal of Immunology, vol. 60, no. 1, pp. 199-208, 2004.
9. C. Duftner, C. Dejaco, W. Kullich et al., "Preferential type 1 chemokine receptors and cytokine production of CD28-T cells in ankylosing spondylitis," Annals of the Rheumatic Diseases, vol. 65, no. 5, pp. 647-653, 2006.
10. E. Bryl, A. N. Vallejo, C. M. Weyand, and J. J. Goronzy, "Down-regulation of CD28 expression by TNF-α," The Journal of Immunology, vol. 167, no. 6, pp. 3231-3238, 2001.
11. E. Bryl, A. N. Vallejo, E. L. Matteson, J. M. Witkowski, C. M. Weyand, and J. J. Goronzy, "Modulation of CD28 expression with anti-tumor necrosis factor α therapy in rheumatoid arthritis," Arthritis and Rheumatism, vol. 52, no. 10, pp. 2996-3003, 2005.
12. V. Rizzello, G. Liuzzo, S. Brugaletta, A. Rebuzzi, L. M. Biasucci, and F. Crea, "Modulation of CD4+CD28null T lymphocytes by tumor necrosis factor-α blockade in patients with unstable angina," Circulation, vol. 113, no. 19, pp. 2272-2277, 2006.
13. J. J. Goronzy, J.W. Fulbright, C. S. Crowson, G. A. Poland, W.M. O'Fallon, and C. M. Weyand, "Value of immunological markers in predicting responsiveness to influenza vaccination in elderly individuals," Journal of Virology, vol. 75, no. 24, pp. 12182-12187, 2001.
14. Y. O. S. H. Morishita, H. Sao, J. A. Hansen, and P. J. Martin, "A distinct subset of human CD4+ cells with a limited alloreactive T cell receptor repertoire," The Journal of Immunology, vol. 143, no. 9, pp. 2783-2789, 1989.
15. C. Dejaco, C. Duftner, A. Klauser, and M. Schirmer, "Altered T-cell subtypes in spondyloarthritis, rheumatoid arthritis and polymyalgia rheumatica," Rheumatology International, vol. 30, no. 3, pp. 297-303, 2010.
16. +CD28-T cells from rheumatoid arthritis patients," Journal of Immunology, vol. 161, no. 2, pp. 1018-1025, 1998.
17. -T cells in ankylosing spondylitis.," Arthritis Research & Therapy, vol. 5, no. 5, pp. R292-R300, 2003.
18. A. E. R. Fasth, M. Dastmalchi, A. Rahbar et al., "T cell infiltrates in the muscles of patients with dermatomyositis and polymyositis are dominated by CD28null T cells," The Journal of Immunology, vol. 183, no. 7, pp. 4792-4799, 2009.
19. C. Dejaco, C. Duftner, J. Al-Massad et al., "NKG2D stimulated T-cell autoreactivity in giant cell arteritis and polymyalgia rheumatica," Annals of the Rheumatic Diseases, vol. 72, no. 11, pp. 1852-1859, 2013.
20. +CD28null T cells in coronary artery disease: when helpers become killers," Cardiovascular Research, vol. 81, no. 1, pp. 11-19, 2009.
21. P. Lamprecht, F. Moosig, E. Csernok et al., "CD28 negative T cells are enriched in granulomatous lesions of the respiratory tract in Wegener's granulomatosis," Thorax, vol. 56, no. 10, pp. 751-757, 2001.
22. M. J. Pinto-Medel, J. A. García-León, B. Oliver-Martos et al., "The CD4+ T-cell subset lacking expression of the CD28 costimulatory molecule is expanded and shows a higher activation state in multiple sclerosis," Journal of Neuroimmunology, vol. 243, no. 1-2, pp. 1-11, 2012.
23. +CD28null T cells," Journal of Clinical Immunology, vol. 24, no. 2, pp. 185-196, 2004.
24. G. Liuzzo, S. L. Kopecky, R. L. Frye et al., "Perturbation of the T-cell repertoire in patients with unstable angina," Circulation, vol. 100, no. 21, pp. 2135-2139, 1999.
25. +CD28-lymphocytes and the extent and severity of coronary artery disease," International Journal of Cardiology, vol. 135, no. 1, pp. 27-35, 2009.
26. G. Liuzzo, J. J. Goronzy, H. Yang et al., "Monoclonal T-cell proliferation and plaque instability in acute coronary syndromes," Circulation, vol. 101, no. 25, pp. 2883-2888, 2000.
27. C. Duftner, R. Seiler, P. Klein-Weigel et al., "High prevalence of circulating CD4+CD28-T-cells in patients with small abdominal aortic aneurysms," Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 25, no. 7, pp. 1347-1352, 2005.
28. +CD28-T cells in patients with chronic kidney graft rejection," Transplantation Proceedings, vol. 35, no. 8, pp. 2902-2904, 2003.
29. +, cytomegalovirus-specific T cell subset after recovery of primary cytomegalovirus infection," Journal of Immunology, vol. 173, no. 3, pp. 1834-1841, 2004.
30. J. van Bergen, E. M. C. Kooy-Winkelaar, H. van Dongen et al., "Functional killer Ig-like receptors on humanmemory CD4+ T cells specific for cytomegalovirus," The Journal of Immunology, vol. 182, no. 7, pp. 4175-4182, 2009.
31. + T cells down-regulates the expression of CD28: effect on T cell activation and cytokine production," Clinical Immunology and Immunopathology, vol. 77, no. 3, pp. 262-270, 1995.
32. R. Kämmerer, A. Iten, P. C. Frei, and P. Bürgisser, "Expansion of T cells negative for CD28 expression in HIV infection. Relation to activation markers and cell adhesion molecules, and correlation with prognosticmarkers," Medical Microbiology and Immunology, vol. 185, no. 1, pp. 19-25, 1996.
33. - cells from chagasic patients: distinct repertoire and cytokine expression," Clinical & Experimental Immunology, vol. 137, no. 1, pp. 129-138, 2004.
34. null T cells in patients with chronic hepatitis B," Immunological Investigations, vol. 38, no. 5, pp. 434-446, 2009.
35. B. Broux, S. Markovic-Plese, P. Stinissen, and N. Hellings, "Pathogenic features of CD4+CD28-T cells in immune disorders," Trends in Molecular Medicine, vol. 18, no. 8, pp. 446-453, 2012.
36. A. N. Vallejo, C. M. Weyand, and J. J. Goronzy, "T-cell senescence: a culprit of immune abnormalities in chronic inflammation and persistent infection," Trends in Molecular Medicine, vol. 10, no. 3, pp. 119-124, 2004.
37. null T cells in rheumatoid arthritis use distinct combinations of T cell receptor BV and BJ elements," European Journal of Immunology, vol. 33, no. 1, pp. 79-84, 2003.
38. M. López-Botet, A. Muntasell, and C. Vilches, "The CD94/NKG2C+ NK-cell subset on the edge of innate and adaptive immunity to human cytomegalovirus infection," Seminars in Immunology, vol. 26, no. 2, pp. 145-151, 2014.
39. J. Olsson, A. Wikby, B. Johansson, S. Löfgren, B. O. Nilsson, and F. G. Ferguson, "Age-related change in peripheral blood Tlymphocyte subpopulations and cytomegalovirus infection in the very old: the Swedish Longitudinal OCTO Immune Study," Mechanisms of Ageing and Development, vol. 121, no. 1-3, pp. 187-201, 2001.
40. + T cells in healthy carriers are continuously driven to replicative exhaustion," Journal of Immunology, vol. 175, no. 12, pp. 8218-8225, 2005.
41. C. Söderberg-Nauclér, "HCMV microinfections in inflammatory diseases and cancer," Journal of Clinical Virology, vol. 41, no. 3, pp. 218-223, 2008.
42. - T cells in rheumatoid arthritis," The Journal of Rheumatology, vol. 26, no. 7, pp. 1452-1457, 1999.
43. null T cells in patients with acute coronary syndromes," Circulation, vol. 109, no. 10, pp. 1230-1235, 2004.
44. W. van Eden, R. van der Zee, and B. Prakken, "Heat-shock proteins induce T-cell regulation of chronic inflammation," Nature Reviews Immunology, vol. 5, no. 4, pp. 318-330, 2005.
45. - T cell proinflammatory and effector responses in patients with coronary artery disease," The Journal of Immunology, vol. 181, no. 8, pp. 5233-5241, 2008.
46. J. H. Yen, B. E. Moore, T. Nakajima et al., "Major histocompatibility complex class I-recognizing receptors are disease risk genes in rheumatoid arthritis," The Journal of Experimental Medicine, vol. 193, no. 10, pp. 1159-1167, 2001.
47. L. Hayflick and P. S. Moorhead, "Theserial cultivation of human diploid cell strains," Experimental Cell Research, vol. 25, no. 3, pp. 585-621, 1961.
48. H. F. Valenzuela and R. B. Effros, "Divergent telomerase and CD28 expression patterns in human CD4 and CD8 T cells following repeated encounters with the same antigenic stimulus," Clinical Immunology, vol. 105, no. 2, pp. 117-125, 2002.
49. R. B. Effros and G. Pawelec, "Replicative senescence of T cells: does the Hayflick Limit lead to immune exhaustion?" Immunology Today, vol. 18, no. 9, pp. 450-454, 1997.
50. C. M. Counter, A. A. Avilion, C. E. LeFeuvre et al., "Telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity," The EMBO Journal, vol. 11, no. 5, pp. 1921-1929, 1992.
51. K. Koetz, E. Bryl, K. Spickschen, W. M. O'Fallon, J. J. Goronzy, and C. M. Weyand, "T cell homeostasis in patients with rheumatoid arthritis," Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 16, pp. 9203-9208, 2000.
52. J. Fessler, A. Raicht, R. Husic et al., "Premature senescence of Tcell subsets in axial spondyloarthritis," Annals of the Rheumatic Diseases, 2015.
53. F. A. Harding, J. G. McArthur, J. A. Gross, D. H. Raulet, and J. P. Allison, "CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones," Nature, vol. 356, no. 6370, pp. 607-609, 1992.
54. - cells," European Journal of Immunology, vol. 27, no. 5, pp. 1082-1090, 1997.
55. null T cells are associated with defects in apoptotic pathways," Journal of Immunology, vol. 165, no. 11, pp. 6301-6307, 2000.
56. P. H. Krammer, "CD95(APO-1/Fas)-mediated apoptosis: live and let die," Advances in Immunology, vol. 71, pp. 163-210, 1999.
57. T. Kataoka, M. Schröter, M. Hahne et al., "FLIP prevents apoptosis induced by death receptors but not by perforin/granzyme B, chemotherapeutic drugs, and gamma irradiation," The Journal of Immunology, vol. 161, no. 8, pp. 3936-3942, 1998.
58. - T cells in the aging immune system," Mechanisms of Ageing and Development, vol. 102, no. 2-3, pp. 131-147, 1998.
59. T. Namekawa, U. G. Wagner, J. J. Goronzy, and C. M. Weyand, "Functional subsets of CD4 T cells in rheumatoid synovitis," Arthritis & Rheumatism, vol. 41, no. 12, pp. 2108-2116, 1998.
60. + T cells to Th1cells requiresMAPkinase JNK2," Immunity, vol. 9, no. 4, pp. 575-585, 1998.
61. I. E. Dumitriu, P. Baruah, C. J. Finlayson et al., "High levels of costimulatory receptors OX40 and 4-1BB characterize CD4+CD28null T cells in patients with acute coronary syndrome," Circulation Research, vol. 110, no. 6, pp. 857-869, 2012.
62. T. Nakajima, S. Schulte;, K. J. Warrington et al., "T-cellmediated lysis of endothelial cells in acute coronary syndromes," Circulation, vol. 105, no. 5, pp. 570-575, 2002.
63. E. Liaskou, L. E. Jeffery, P. J. Trivedi et al., "Loss of CD28 expression by liver-infiltrating T cells contributes to pathogenesis of primary sclerosing cholangitis," Gastroenterology, vol. 147, no. 1, pp. 221.e7-232.e7, 2014.
64. R. Gerli, G. Schillaci, A. Giordano et al., "CD4+CD28-T lymphocytes contribute to early atherosclerotic damage in rheumatoid arthritis patients," Circulation, vol. 109, no. 22, pp. 2744-2748, 2004.
65. A. Pawlik, L. Ostanek, I. Brzosko et al., "Therapy with infliximab decreases the CD4+CD28-T cell compartment in peripheral blood in patients with rheumatoid arthritis," Rheumatology International, vol. 24, no. 6, pp. 351-354, 2004.
66. S. Giubilato, G. Liuzzo, S. Brugaletta et al., "Expansion of CD4+CD28null T-lymphocytes in diabetic patients: exploring new pathogenetic mechanisms of increased cardiovascular risk in diabetes mellitus," European Heart Journal, vol. 32, no. 10, pp. 1214-1226, 2011.
67. V. Pasceri, J. T. Willerson, and E. T. H. Yeh, "Direct proinflammatory effect of C-reactive protein on human endothelial cells," Circulation, vol. 102, no. 18, pp. 2165-2168, 2000.
68. null T cells from rheumatoid arthritis patients show distinct characteristics," Scandinavian Journal of Immunology, vol. 79, no. 2, pp. 149-155, 2014.
69. A. N. Vallejo, "CD28 extinction in human T cells: altered functions and the programof T-cell senescence," Immunological Reviews, vol. 205, pp. 158-169, 2005.
70. V. Groh, A. Brühl, H. El-Gabalawy, J. L. Nelson, and T. Spies, "Stimulation of T cell autoreactivity by anomalous expression of NKG2D and its MIC ligands in rheumatoid arthritis," Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 16, pp. 9452-9457, 2003.
71. null T cells clonally expanded in rheumatoid arthritis," The Journal of Immunology, vol. 165, no. 2, pp. 1138-1145, 2000.
72. K. J. Warrington, S. Takemura, J. J. Goronzy, and C.M. Weyand, "CD4+, CD28-T cells in rheumatoid arthritis patients combine features of the innate and adaptive immune systems," Arthritis & Rheumatism, vol. 44, no. 1, pp. 13-20, 2001.
73. null T-helper cells in ankylosing spondylitis," Arthritis Research & Therapy, vol. 7, no. 6, pp. R1412-1420, 2005.
74. - T cells into the brain ofmultiple sclerosis patients," Journal of Autoimmunity, vol. 38, no. 1, pp. 10-19, 2012.
75. F. Facchetti, C. Appiani, L. Salvi, J. Levy, and L. D. Notarangelo, "Immunohistologic analysis of ineffective CD40-CD40 ligand interaction in lymphoid tissues from patients with X-linked immunodeficiency with hyper-IgM: abortive germinal center cell reaction and severe depletion of follicular dendritic cells," The Journal of Immunology, vol. 154, no. 12, pp. 6624-6633, 1995.
76. null T cells in bronchiolitis obliterans syndrome," Clinical & Experimental Immunology, vol. 173, no. 1, pp. 150-160, 2013.
77. H. Sawai, Y. W. Park, J. Roberson, T. Imai, J. J. Goronzy, and C. M. Weyand, "T cell costimulation by Fractalkine-Expressing synoviocytes in rheumatoid arthritis," Arthritis & Rheumatism, vol. 52, no. 5, pp. 1392-1401, 2005.
78. 3CR1 in rheumatoid arthritis patients," Acta Medica Okayama, vol. 61, no. 2, pp. 89-98, 2007.
79. M. V. Volin, J. M. Woods, M. A. Amin, M. A. Connors, L. A. Harlow, and A. E. Koch, "Fractalkine: a novel angiogenic chemokine in rheumatoid arthritis," The American Journal of Pathology, vol. 159, no. 4, pp. 1521-1530, 2001.
80. A. N. Vallejo, L. O. Mügge, P. A. Klimiuk, C. M. Weyand, and J. J. Goronzy, "Central role of thrombospondin-1 in the activation and clonal expansion of inflammatory T cells," The Journal of Immunology, vol. 164, no. 6, pp. 2947-2954, 2000.
81. + T cells in rheumatoid arthritis," Arthritis & Rheumatism, vol. 52, no. 12, pp. 3839-3849, 2005.
82. C. Duftner, C. Dejaco, and M. Schirmer, "Early aged T-cells in immune-mediated diseases," Current Immunology Reviews, vol. 7, no. 1, pp. 124-132, 2011.
83. M. R. Snyder, C. M. Weyand, and J. J. Goronzy, "The double life of NK receptors: stimulation or co-stimulation?" Trends in Immunology, vol. 25, no. 1, pp. 25-32, 2004.
84. S. Bauer, V. Groh, J. Wu et al., "Activation of NK cells and T cells byNKG2D, a receptor for stress-inducibleMICA," Science, vol. 285, no. 5428, pp. 727-729, 1999.
85. V. Groh, J. Wu, C. Yee, and T. Spies, "Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation," Nature, vol. 419, no. 6908, pp. 734-738, 2002.
86. G. David, Z. Djaoud, C. Willem et al., "Large spectrum of HLA-C recognition by killer Ig-like receptor (KIR)2DL2 and KIR2DL3 and restricted C1 specificity of KIR2DS2: dominant impact of KIR2DL2/KIR2DS2 on KIR2D NK cell repertoire formation," Journal of Immunology, vol. 191, no. 9, pp. 4778-4788, 2013.
87. - T cells and their pathogenic role in nondialysis and dialysis dependent chronic kidney disease patients," Immunology, 2014.
88. O. Takeuchi and S. Akira, "Pattern recognition receptors and inflammation," Cell, vol. 140, no. 6, pp. 805-820, 2010.
89. R. S. Schwartz, M.G. Netea, and J.W. van der Meer, "Immunodeficiency and genetic defects of pattern-recognition receptors," New England Journal of Medicine, vol. 364, pp. 60-70, 2011.
90. T. Kawai and S. Akira, "TLR signaling," Cell Death and Differentiation, vol. 13, no. 5, pp. 816-825, 2006.
91. S. Sivori, S. Carlomagno, S. Pesce, A. Moretta, M. Vitale, and E. Marcenaro, "TLR/NCR/KIR: Which one to use and when?" Frontiers in Immunology, vol. 5, article 105, 2014.
92. M. Croft and C. Dubey, "Accessory molecule and costimulation requirements for CD4 T cell response," Critical Reviews in Immunology, vol. 17, no. 1, pp. 89-118, 1997.
93. M. I. Reinhold, F. P. Lindberg, G. J. Kersh, P. M. Allen, and E. J. Brown, "Costimulation of T cell activation by integrinassociated protein (CD47) is an adhesion-dependent, CD28-independent signaling pathway," The Journal of Experimental Medicine, vol. 185, no. 1, pp. 1-11, 1997.
94. A. N. Vallejo, H. Yang, P. A. Klimiuk, C. M. Weyand, and J. J. Goronzy, "Synoviocyte-mediated expansion of inflammatory T cells in rheumatoid synovitis is dependent on CD47-thrombospondin 1 interaction," The Journal of Immunology, vol. 171, no. 4, pp. 1732-1740, 2003.
95. H. Hoff, K. Knieke, Z. Cabail et al., "Surface CD152 (CTLA-4) expression and signaling dictates longevity of CD28null T cells," Journal of Immunology, vol. 182, no. 9, pp. 5342-5351, 2009.
96. M. Croft, "Costimulation of T cells by OX40, 4-1BB, and CD27," Cytokine and Growth Factor Reviews, vol. 14, no. 3-4, pp. 265-273, 2003.
97. T. So, S.W. Lee, and M. Croft, "Immune regulation and control of regulatory T cells by OX40 and 4-1BB," Cytokine and Growth Factor Reviews, vol. 19, no. 3-4, pp. 253-262, 2008.
98. - T cells are a major source of interferon-γ and tumor necrosis factor-α in Wegener's granulomatosis," The American Journal of Pathology, vol. 160, no. 5, pp. 1717-1724, 2002.
99. null T cells in rheumatoid arthritis," Arthritis Research & Therapy, vol. 9, no. 5, article R87, 2007.
100. + T cells in severe rheumatoid arthritis," Arthritis & Rheumatism, vol. 40, no. 6, pp. 1106-1114, 1997.
101. K. J. Warrington, P. D. Kent, R. L. Frye et al., "Rheumatoid arthritis is an independent risk factor for multi-vessel coronary artery disease: a case control study," Arthritis Research & Therapy, vol. 7, no. 5, pp. R984-R991, 2005.
102. Z. G. Nadareishvili, H. Li, V. Wright et al., "Elevated proinflammatory CD4+CD28-lymphocytes and stroke recurrence and death," Neurology, vol. 63, no. 8, pp. 1446-1451, 2004.
103. null T cells in patients with coronary artery disease and individuals with risk factors for atherosclerosis," Cellular Immunology, vol. 281, no. 1, pp. 11-19, 2013.
104. A. K. Yadav, A. Lal, and V. Jha, "Cytotoxic CD4+CD28null T lymphocytes, systemic inflammation and atherosclerotic risk in patients with chronic kidney disease," Nephron Clinical Practice, vol. 120, no. 4, pp. c185-c193, 2012.
105. - T cell expansion in granulomatosis with polyangiitis (Wegener's) is driven by latent cytomegalovirus infection and is associated with an increased risk of infection and mortality," Arthritis and Rheumatism, vol. 63, no. 7, pp. 2127-2137, 2011.
106. M. Feldmann and R. N. Maini, "Anti-TNFα therapy of rheumatoid arthritis: what have we learned?" Annual Review of Immunology, vol. 19, pp. 163-196, 2001.
107. null T lymphocyte frequency in patients with unstable angina," Heart, vol. 92, no. 2, pp. 249-250, 2006.
108. F. Cipollone, A. Mezzetti, E. Porreca et al., "Association between enhanced soluble CD40L and prothrombotic state in hypercholesterolemia: effects of statin therapy," Circulation, vol. 106, no. 4, pp. 399-402, 2002.
109. H. F. Alber, M. Frick, A. Suessenbacher et al., "Effect of atorvastatin on circulating proinflammatory T-lymphocyte subsets and soluble CD40 ligand in patients with stable coronary artery disease-a randomized, placebo-controlled study," The American Heart Journal, vol. 151, no. 1, pp. 139.e1-139.e7, 2006.
110. M. Scarsi, T. Ziglioli, and P. Airo, "Decreased circulating CD28-negative T cells in patients with rheumatoid arthritis treated with abatacept are correlated with clinical response," The Journal of Rheumatology, vol. 37, no. 5, pp. 911-916, 2010.
111. C. Dejaco, C. Duftner, E. Wipfler, and M. Schirmer, "A novel treatment option in rheumatoid arthritis: abatacept, a selective modulator of T-cell co-stimulation," Wiener Medizinische Wochenschrift, vol. 159, no. 3-4, pp. 70-75, 2009.
112. P. Mease, M. C. Genovese, G. Gladstein et al., "Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebocontrolled, phase II trial," Arthritis & Rheumatism, vol. 63, no. 4, pp. 939-948, 2011.
113. - T-cells," PLoS ONE, vol. 7, no. 3, Article IDe33939, 2012.
114. C. Ziegler, J. Finke, and C. Grüllich, "Rabbit anti-T-lymphocyte globulin (ATG) persists with differential reactivity in patients' sera after full hematopoetic regeneration from allogeneic stem cell transplantation," Transplant Immunology, vol. 30, no. 4, pp. 136-139, 2014.